Full-Time
Metalworker/Mechatronics Technician
Posted on 9/7/2026
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Mannheim, Germany
In Person
 General Maintenance & Repair (1) |
|---|
Get referred to Roche
See people who can refer or advise you
- Completed vocational training as a metalworker or mechatronics technician.
- Relevant professional experience in pharmaceutical production.
- Experience and knowledge with special-purpose equipment, such as batch preparation and filling equipment or packaging equipment and packaging technology.
- Experience with electropneumatic controls, common information technology applications including Microsoft Office, and SAP R/3.
- Familiarity with systematic fault analysis on production equipment.
- Ability to describe complex matters clearly in writing and verbally.
- Practical aptitude, independence, willingness to learn, and self-motivation.
- Good knowledge of working in hygienic environments and familiarity with applicable Good Manufacturing Practice guidelines.
- Ability and openness to recognize the opportunities and benefits of change and explain the reasons for it.
- Willingness to work in a three-shift operation and, when needed, continuous shift coverage including morning, evening, and night shifts and potentially Saturdays.
- Help maintain an optimal production operation.
- Independently repair machines within the assigned area and maintain the functionality of safety devices.
- Perform machine format changes and maintenance according to instructions, work procedures, and maintenance schedules.
- Document completed work according to applicable Good Manufacturing Practice requirements in documents such as manufacturing instructions, technical logs, and I/W plans.
- Regulate technical functional and control units according to applicable technical specifications.
- Follow all applicable procedures and guidelines, including work instructions, maintenance schedules, and safety regulations.
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
- FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
- Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.
What critics are saying
- Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
- Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
- Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.
What makes Roche unique
- Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
- Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
- Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.
Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.
Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.
CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.
Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.